

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David P. Andrew, Brian A. Zabel and Paul D. Ponath

Divisional of

Application No.: 09/266,464

Filed: March 11, 1999

Title: METHODS OF IDENTIFYING AGENTS WHICH INHIBIT GPR-9-6

Date: 9-28-01

EXPRESS MAIL LABEL NO. EL551546111US

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

jc821 U.S. PRO
09/09/966755
09/28/01

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

Copies of the cited references are enclosed.

Copies of cited references are enclosed except those entered in prior application, U.S. Application No. 09/266,464, to which priority under 35 U.S.C. 120 is claimed.

The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:

the explanation provided on the attached sheet.

the explanation provided in the Specification.

submission of the enclosed International Search Report.

the enclosed English language abstract.

[] Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner _____

Date _____

[] A copy of each above-cited application, including the current claims, is enclosed.
[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
[] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Robert H. Underwood
Robert H. Underwood
Registration No.: 45,170
Telephone (978) 341-0036
Facsimile (978) 341-0136

Lexington, Massachusetts 02421-4799
Dated: September 28, 2001

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 1855.1064-010	APPLICATION NO.			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION September 28, 2001 (Use several sheets if necessary)			APPLICANTS David P. Andrew, Brian A. Zabel and Paul D. Ponath			S. PTO 16821 09/28/01 966755	
			FILING DATE September 28, 2001	GROUP Unknown			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,652,133	29 JUL 97	Murphy	435	325	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 98/01557	15 JAN 98	PCT			
	AM	WO 98/32858	30 JUL 98	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Yoshida, R., et al., "Molecular Cloning of a Novel Human CC Chemokine EBI1-ligand Chemokine That is a Specific Functional Ligand for EBI1, CCR7," <i>J. Biol. Chem.</i> , 272(21):13803-13809 (1997).					
	AS	Baba, M., et al., "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC," <i>J. Biol. Chem.</i> , 272(23):14893-14898 (1997).					
	AT	Imai, T., et al., "The T Cell-directed CC Chemokine TARC is a Highly Specific Biological Ligand for CC Chemokine Receptor 4," <i>J. Biol. Chem.</i> , 272(23):15036-15042 (1997).					
	AU	Kitaura, M., et al., "Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3," <i>J. Biol. Chem.</i> , 271(13):7725-7730 (1996).					
	AV	Vicari, A.P., et al., "TECK: A Novel CC Chemokine Specifically Expressed by Thymic Dendritic Cells and Potentially Involved in T Cell Development," <i>Immunity</i> , 7:291-301 (1997).					
	AW	Damon, I., et al., "Broad Spectrum Chemokine Antagonistic Activity of a Human Poxvirus Chemokine Homolog," <i>Proc. Natl. Acad. Sci. USA</i> , 95:6403-6407 (1998).					
	AX	O'Garra A., et al., "T-Cell Subsets: Chemokine Receptors Guide the Way," <i>Current Biology</i> , 8:R646-R649 (1998).					
	AY	Kim, C.H., et al., "Chemokines: Signal Lamps for Trafficking of T and B Cells for Development of Effector Function," <i>J. Leukoc. Biol.</i> , 65:6-15 (1999).					
	AZ	Murphy, P.M., "The Molecular Biology of Leukocyte Chemoattractant Receptors," <i>Annu. Rev. Immunol.</i> , 12:593-633 (1994).					
	AR2	Zlotnik, A., et al., "Recent Advances in Chemokines and Chemokine Receptors," <i>Critical Reviews™ in Immunology</i> , 19:1-47 (1999).					
EXAMINER			DATE CONSIDERED				

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
1855.1064-010

APPLICATION NO.

INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

September 28, 2001

(Use several sheets if necessary)

APPLICANTS

David P. Andrew, Brian A. Zabel
and Paul D. Ponath

FILING DATE

September 28, 2001

GROUP

Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AS2	Nomiyama, H., et al., "The Human CC Chemokine TECK (SCYA25) Maps to Chromosome 19p13.2," <i>Genomics</i> , 51:311-312 (1998).
	AT2	Vicari, A.P., et al., "TECK: A Novel CC Chemokine Associated with T-Cell Development," <i>J. Allergy Clin. Immunol.</i> , 99(1):S246, Abstract No. 1003, (1997).
	AU2	Combadiere, C., et al., "Cloning and Functional Expression of Two Human CC Chemokine Receptors," <i>FASEB J.</i> , 10(6):A1093, Abstract No. 545 (1996).
	AV2	Gao, J.-L., et al., "Cloning and Expression of the Mouse MIP-1 α Receptor Gene and Two Related Genes," <i>9th International Congress of Immunology</i> , p. 108, Abstract No. 637 (1995).
	AW2	GenBank Accession No. U45982, "Human G Protein Coupled Receptor GPR-9-6 Gene, Complete CDS," (1996).
	AX2	Zaballos, A., et al., "Cutting Edge: Identification fo the Orphan Chemokine Receptor GPR-9-6 as CCR9, the Receptor for the Chemokine TECK," <i>J. Immunol.</i> , 162(10):5671-5675 (1999).
	AY2	Chuntharapai, A. and Kim, K.J., "Generation of Monoclonal Antibodies to Chemokine Receptors," <i>Methods of Enzymology</i> , 288:15-27 (1997).
	AZ2	Locati, M., et al., "Chemokines and Chemokine Receptors: Biology and Clinical Relevance in Inflammation and AIDS," <i>Annu. Rev. Med.</i> , 50:425-440 (1999).
	AR3	Zabel, B.A., et al., Human G Protein-coupled Receptor GPR-9-6/CC Chemokine Receptor 9 is Selectively Expressed on Intestinal Homing T Lymphocytes, Mucosal Lymphocytes, and Thymocytes and is Required for Thymus-expressed Chemokine-mediated Chemotaxis," <i>J. Exp. Med.</i> , 190(9):1241-1255 (1999).
	AS3	Swissprot Database, Accession No. P51686, "Probable G-Protein-Coupled Receptor GPR-9-6" [online], October 1996.
	AT3	Nibbs, R.J.B., et al., "Cloning and Characterization of a Novel Promiscuous Human β -Chemokine Receptor D6," <i>J. Biol. Chem.</i> , 272(51):32078-32083 (1997).
	AU3	Murphy, P.M., et al., "International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors," <i>Pharmacol. Rev.</i> , 52(1):145-176 (2000).
	AV3	Youn, B-S, et al., "TECK, an Efficacious Chemoattractant for Human Thymocytes, Uses GPR-9-6/CCR9 as a Specific Receptor," <i>Blood</i> , 94(7):2533-2536 (1999).
	AW3	Attwood, T.K., "The Babel of Bioinformatics," <i>SCIENCE</i> , 290:471-473.
EXAMINER		DATE CONSIDERED